Navitoclax (ABT-263), a BCL-2/BCL-XL/BCL-W inhibitor, showed strong effects against chronic lymphocytic leukemia (CLL), but also resulted in severe thrombocytopenia7. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.